1. Home
  2. HR vs GKOS Comparison

HR vs GKOS Comparison

Compare HR & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Healthcare Realty Trust Incorporated

HR

Healthcare Realty Trust Incorporated

HOLD

Current Price

$20.11

Market Cap

6.5B

Sector

Real Estate

ML Signal

HOLD

Logo Glaukos Corporation

GKOS

Glaukos Corporation

HOLD

Current Price

$133.77

Market Cap

6.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HR
GKOS
Founded
1992
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Medical/Dental Instruments
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.5B
6.0B
IPO Year
2006
2015

Fundamental Metrics

Financial Performance
Metric
HR
GKOS
Price
$20.11
$133.77
Analyst Decision
Hold
Strong Buy
Analyst Count
8
12
Target Price
$19.29
$126.92
AVG Volume (30 Days)
4.1M
676.3K
Earning Date
04-30-2026
04-29-2026
Dividend Yield
5.20%
N/A
EPS Growth
60.77
N/A
EPS
N/A
N/A
Revenue
$1,180,546,000.00
$507,442,000.00
Revenue This Year
N/A
$23.32
Revenue Next Year
$3.14
$27.43
P/E Ratio
N/A
N/A
Revenue Growth
N/A
32.33
52 Week Low
$14.09
$73.16
52 Week High
$20.46
$146.75

Technical Indicators

Market Signals
Indicator
HR
GKOS
Relative Strength Index (RSI) 72.42 60.53
Support Level $17.44 $80.14
Resistance Level N/A $146.75
Average True Range (ATR) 0.40 5.73
MACD 0.17 0.54
Stochastic Oscillator 87.24 60.71

Price Performance

Historical Comparison
HR
GKOS

About HR Healthcare Realty Trust Incorporated

Healthcare Realty Trust Inc is a healthcare facility real estate investment trust. The company focuses on owning, leasing, and managing outpatient facilities and other healthcare properties. The company works to invest in outpatient facilities that are integral to a hospital's operations. It generates all of its revenue in the United States.

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Share on Social Networks: